Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2926MR)

This product GTTS-WQ2926MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ2926MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10372MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ754MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AAB-001
GTTS-WQ8213MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ12341MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ6432MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ10714MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ2712MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG103
GTTS-WQ151MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 124I_WX-G250
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW